STRN-ALK Fusion in Lung Adenocarcinoma with Excellent Response Upon Alectinib Treatment: A Case Report and Literature Review

Non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase (ALK) rearrangement benefit from treatment with ALK inhibitors. Therefore, the identification of druggable ALK fusions is necessary for NSCLC treatment. More than 90 fusion partners of ALK have been reported in NSCLC patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Cuiyun, Jiang, Ya, Jiang, Wei, Wang, Huilin, Liu, Sisi, Shao, Yang, Zhao, Wenhua, Ning, Ruiling, Yu, Qitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727031/
https://www.ncbi.nlm.nih.gov/pubmed/33311990
http://dx.doi.org/10.2147/OTT.S282933

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727031/
https://www.ncbi.nlm.nih.gov/pubmed/33311990
http://dx.doi.org/10.2147/OTT.S282933

Ejemplares similares